Clinical trial
Treatments Against RA and Effect on FDG-PET/CT
NCT02374021
Study timeline
Study start (unknown)2016-07-01Date precision: month
Registry last updated2022-10-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Arthritis, Rheumatoidunresolved
Interventions
MethotrexateDRUG · verified · RxNorm: methotrexate
SulfasalazineDRUG · verified · RxNorm: sulfasalazine
HydroxychloroquineDRUG · verified · RxNorm: hydroxychloroquine
EtanerceptDRUG · verified · RxNorm: etanercept
AdalimumabDRUG · verified · RxNorm: adalimumab
Sponsors & collaborators
Brigham and Women's Hospitallead sponsor
Columbia Universitycollaborator
Mapped research locations
New YorkNew York, United States3BostonMassachusetts, United States2HoustonTexas, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1ClevelandOhio, United States1PittsburghPennsylvania, United States1BirminghamAlabama, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02374021 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.